You're contacting media contact of this press release

Title: Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia XLH

United States, 24th Jul 2025– Anzor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead investigational therapy, a novel FGF23 peptide antagonist, for the treatment of X-linked hypophosphatemia (XLH), a rare and debilitating genetic disorder.XLH is a serious, lifelong disease affecting approximately 1 in 20,000 individuals, characterized by excessive phosphate excretion, rickets, osteomalacia, poor bone development, dental problems, and significant morbidity in both children and adults. The disorder results from excess activity of the hormone fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia and its downstream effects.The FGF23 peptide antagonist being developed by Anzor Pharmaceuticals aims to selectively block the excessive activity of FGF23. Preclinical data indicate that antagonizing FGF23 can normalize phosphate homeostasis, improve bone integrity, and provide a targeted therapy with an improved safety profile compared to current options. This approach directly targets the disease mechanism rather than only addressing symptoms.Orphan Drug Designation by the FDA is granted to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases affecting fewer than 200,000 people in the United States. This status provides important incentives for Anzor Pharmaceuticals, including tax credits for clinical testing, relief from certain FDA fees, and, if approved, seven years of marketing exclusivity for the FGF23 peptide antagonist in XLH.“Receiving Orphan Drug Designation from the FDA is a significant milestone that advances our commitment to patients and families affected by XLH,” said a spokesperson for Anzor Pharmaceuticals. “We...

This press release is issued by King Newswire